Abstract
Cancer patients are vulnerable to COVID-19 with consequences on treatment delays and on mortality rate. This Comment explores the interaction between COVID-19 and cancer with attention paid to the modulation by cancer treatments of both ADAM17 and TMPRSS2, the proteases which control ACE2 processing, the SARS-CoV-2 target.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
ADAM17 Protein / genetics*
-
Angiotensin-Converting Enzyme 2 / genetics
-
COVID-19 / complications
-
COVID-19 / epidemiology
-
COVID-19 / genetics*
-
COVID-19 / virology
-
Humans
-
Mortality
-
Neoplasms / complications
-
Neoplasms / epidemiology
-
Neoplasms / genetics*
-
Neoplasms / virology
-
SARS-CoV-2 / genetics
-
SARS-CoV-2 / pathogenicity
-
Serine Endopeptidases / genetics*
Substances
-
Angiotensin-Converting Enzyme 2
-
Serine Endopeptidases
-
TMPRSS2 protein, human
-
ADAM17 Protein
-
ADAM17 protein, human